Anti-proliferative effect and underlying mechanisms of combination of curcumin and adriamycin on breast cancer cells

ANG Guang,YANG Yu,and ZENG Xianyang.

Medical Journal of the Chinese People Armed Police Forces ›› 2013, Vol. 24 ›› Issue (6) : 474-476.

PDF(691 KB)
PDF(691 KB)
Medical Journal of the Chinese People Armed Police Forces ›› 2013, Vol. 24 ›› Issue (6) : 474-476.

Anti-proliferative effect and underlying mechanisms of combination of curcumin and adriamycin on breast cancer cells

  • ANG Guang,YANG Yu,and ZENG Xianyang.
Author information +
History +

Abstract

Objective To investigate the anti-proliferative effect and underlying mechanisms of the combination of curcumin and adriamycin on breast cancer MCF-7 and MDA-MB-231 cells. Methods MTT was used to detect the cell viablility of MCF-7 and MDA-MB-231 cells after different concentrations of curcumin (Cur) and adriamycin(ADM) treatment. Calcusyn software was used for evaluating the combination index (CI). The proteins of PARP, Bcl-2, Bax, and NF-κB (p65) were detected by Western blotting. Results The combination of Cur and ADM synergisticly inhibited the growth of MCF-7 and MDA-MB-231 cells, with the ED50CI of 0.70 and 0.62, respectively. The Western blotting data showed that the combination of Cur and ADM could enhance the cleavage of PARP, and decrease the expression of Bcl-2, but had no affect on the expression of Bax in MCF-7 cells. In addition, we found that the combination treatment could inhibit the activation of NF-κB induced by ADM. Conclusions Cur sensitizes breast cancer to ADM in vitro most likely via inhibiting the activation of NF-κB signaling induced by ADM and subsequent increasing the apoptosis.

Key words

apoptosis / curcumin / adriamycin / NF-κB

Cite this article

Download Citations
ANG Guang,YANG Yu,and ZENG Xianyang.. Anti-proliferative effect and underlying mechanisms of combination of curcumin and adriamycin on breast cancer cells[J]. Medical Journal of the Chinese People Armed Police Forces. 2013, 24(6): 474-476

References

[1] 吕遐晟, 杜哲明, 曾 朋, 等. GLI1 在乳腺癌各分子亚型中的表达及意义[J]. 武警医学. 2012, 23(10):862-865.

[2] 蒋宇翔, 陈 栋, 王 玮, 等. p38MAPK抑制剂增强ADM抑制乳腺癌细胞增殖的体外研究[J]. 浙江理工大学学报.2010, 27(1):130-133.

[3] Von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment[J]. Expert Opin Pharmacother. 2007, 8(4):485-495.

[4] Patel B B, Majumdar A P. Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview[J].Nutr Cancer. 2009,61(6):842-846.

[5] Moreno,Aspitia A, Perez E A. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends[J]. Clin Ther. 2009, 31(8):1619-1640

[6] Esatbeyoglu T, Huebbe P, Ernst I M, et al. Curcumin--from molecule to biological function[J]. Angew Chem Int Ed Engl. 2012,51(22):5308-5332.

[7] Hardwick J M, Chen Y B, Jonas E A.Multipolar functions of BCL-2 proteins link energetics to apoptosis[J]. Trends Cell Biol. 2012, 22(6):318-328.

[8] Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy[J].Biochim Biophys Acta. 2010,1805(2):167-180
PDF(691 KB)

Accesses

Citation

Detail

Sections
Recommended

/